Immunogenicity of anti-tumour necrosis factor therapy in Korean patients with rheumatoid arthritis and ankylosing spondylitis

被引：18

作者：

Jung, Seung Min ^{[1
]}

Kim, Hyun-Sook ^{[2
]}

Kim, Hae-Rim ^{[3
]}

Kim, Na Young ^{[1
]}

Lee, Jung-Hwa ^{[3
]}

Kim, Juryun ^{[4
]}

Kwok, Seung-Ki ^{[1
]}

Park, Kyung-Su ^{[1
]}

Park, Sung-Hwan ^{[1
]}

Kim, Ho-Youn ^{[3
]}

Ju, Ji Hyeon ^{[1
,4
]}

机构：

[1] Catholic Univ Korea, Seoul St Marys Hosp, Div Rheumatol, Dept Internal Med, Seoul 137701, South Korea

[2] Soonchunhyang Univ, Coll Med, Div Rheumatol, Dept Internal Med, Seoul, South Korea

[3] Konkuk Univ, Med Ctr, Dept Internal Med, Div Rheumatol, Seoul, South Korea

[4] Catholic Univ Korea, Seoul St Marys Hosp, CiSTEM Lab, Convergent Res Consortium Immunol Dis, Seoul 137701, South Korea

来源：

INTERNATIONAL IMMUNOPHARMACOLOGY | 2014年 / 21卷 / 01期

关键词：

TNF inhibitor; Immunogenicity; Antidrug antibody; Rheumatoid arthritis; Ankylosing spondylitis; ANTI-ADALIMUMAB ANTIBODIES; LONG-TERM TREATMENT; CLINICAL-RESPONSE; DISEASE-ACTIVITY; INFLIXIMAB; EFFICACY; INTERFERENCE; AGENTS;

D O I：

10.1016/j.intimp.2014.04.006

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The aim of this study was to investigate the prevalence of antidrug antibodies (ADAs) against tumour necrosis factor (TNF) inhibitors in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). ADAs were detected in 18 (9.8%) patients with RA and in 18 (10.2%) patients with AS of the 360 patients. Development of ADAs was significantly associated with treatment failure in RA patients (P = 0.003). When classified by drugs, the prevalence of immunogenicity in descending order was 17 (28.8%) patients treated with infliximab, 17 (10.4%) with adalimumab, and 2 (1.4%) with etanercept After adjustment for disease and duration of anti-TNF therapy, the odds ratio as a reference of adalimumab-treated patients was 9.159 (95% confidence interval [CI] 2.005-41.845) for infliximab and 0.280 (95% CI 0.128-0.611) for etanercept The immunogenicity of anti-TNF therapy was highest in the infliximab-treated group and significantly lower in the etanercept-treated group. (C) 2014 Elsevier B.V. All rights reserved.

引用

收藏

页码：20 / 25

页数：6

相关论文

共 26 条

[1] Immunogenicity of anti-tumor necrosis factor antibodies - toward improved methods of anti-antibody measurement [J].

Aarden, Lucien ;

Ruuls, Sigrid R. ;

Wolbink, Gertjan .

CURRENT OPINION IN IMMUNOLOGY, 2008, 20 (04) :431-435

[2] Immunogenicity of Anti-TNF-α Agents in Autoimmune Diseases [J].

Aikawa, Nadia Emi ;

de Carvalho, Jozelio Freire ;

Almeida Silva, Clovis Artur ;

Bonfa, Eloisa .

CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2010, 38 (2-3) :82-89

[3] Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors. [J].

Anderson P. ;

Louie J. ;

Lau A. ;

Broder M. .

Current Rheumatology Reports, 2005, 7 (1) :3-9

[4] Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease [J].

Baert, F ;

Noman, M ;

Vermeire, S ;

Van Assche, G ;

D'Haens, G ;

Carbonez, A ;

Rutgeerts, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :601-608

[5] Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms [J].

Bartelds, G. M. ;

Wijbrandts, C. A. ;

Nurmohamed, M. T. ;

Wolbink, G. J. ;

de Vries, N. ;

Tak, P. P. ;

Dijkmans, B. A. C. ;

Crusius, J. B. A. ;

van der Horst-Bruinsma, I. E. .

ARTHRITIS AND RHEUMATISM, 2009, 60 (08) :2541-2542

[6] Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis [J].

Bartelds, Geertje M. ;

Wijbrandts, Carla A. ;

Nurmohamed, Michael T. ;

Stapel, Steven ;

Lems, Willem F. ;

Aarden, Lucien ;

Dijkmans, Ben A. C. ;

Tak, Paul Peter ;

Wolbink, Gerrit Jan .

ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (07) :921-926

[7] Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up [J].

Bartelds, Geertje M. ;

Krieckaert, Charlotte L. M. ;

Nurmohamed, Michael T. ;

van Schouwenburg, Pauline A. ;

Lems, Willem F. ;

Twisk, Jos W. R. ;

Dijkmans, A. C. ;

Aarden, Lucien ;

Wolbink, Gerrit Jan .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (14) :1460-1468

[8] Immunogenicity, efficacy and adverse events of adalimumab in RA patients [J].

Bender, Niko K. ;

Heilig, Christoph E. ;

Droell, Benjamin ;

Wohlgemuth, Jessica ;

Armbruster, Franz-Paul ;

Heilig, Bernhard .

RHEUMATOLOGY INTERNATIONAL, 2007, 27 (03) :269-274

[9] Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation [J].

de Vries, Mirjam K. ;

Wolbink, Gerrit Jan ;

Stapel, Steven O. ;

de Vrieze, Henk ;

van denderen, J. Christiaan ;

Dijkmans, Ben A. C. ;

Aarden, Lucien A. ;

van der Horst-Bruinsma, Irene E. .

ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (09) :1252-1254

[10] Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012 [J].

Furst, Daniel E. ;

Keystone, Edward Clark ;

So, Alexander K. ;

Braun, Juergen ;

Breedveld, Ferry C. ;

Burmester, Gerd R. ;

De Benedetti, Fabrizio ;

Doerner, Thomas ;

Emery, Paul ;

Fleischmann, Roy ;

Gibofsky, Allan ;

Kalden, J. R. ;

Kavanaugh, Arthur ;

Kirkham, Bruce ;

Mease, Philip ;

Rubbert-Roth, A. ;

Sieper, Joachim ;

Singer, Nora G. ;

Smolen, Josef S. ;

Van Riel, Piet L. C. M. ;

Weisman, Michael H. ;

Winthrop, Kevin L. .

ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 :2-34